Overview prescribe On Thursday, he unveiled his new list of nearly a hundred medicines that are “more dangerous than beneficial” to avoid because of the health risks “disproportionately” that they throw to patients with newcomers like Decontractyl and anti-cough products.
Among the six drugs added this year to this blacklist, Décontractyl (pills or balm), a medicine used to relieve muscle pain during contracture. The side effects caused by the active ingredient, mefenesin, are mainly drowsiness, nausea, vomiting, severe allergic reactions, as well as abuse and dependence (psychotropic effects). The ointment is subject to serious skin diseases.
Oksomemazin protivokashlevy, which includes a lot of products (Toplexil and which generics Humex Oxomemazine dry cough), which has antipsychotic properties, also undergoes "disproportionate side effects."
The list of 2019, which lists 93 drugs (including 82 sold in France) that should not be used without seeing an exit from the market, was compiled on the basis of analyzes published in a review over nine years, from 2010 to 2018 explained prescribe,
See also: Shortage: 160 marks are not available in Moroccan pharmacies
The list of criticized treatments – cancer, diabetes, osteoarthritis, allergies, skin diseases, Alzheimer's disease, sexuality, cough, smoking cessation, etc. – is huge for serious or good defects. The drugs in question are new or old and outdated, or no better than placebo.
Also this year registered ointment for anal fissures. Rectogesic, no more effective than placebo, but can cause frequent headaches, as well as cimetidine (Cimetidine Milan and others), it is allowed for disorders such as heartburn and acid reflux. Cimetidine undergoes undesirable interactions with many drugs, unlike other products of the same H2-blocker family (“H2-antihistamines”).
Three drugs from the 2018 list were excluded from this updated report, namely an antibiotic withdrawn from the world market (Ketek) and two more because of the new data that is being analyzed prescribe: Uptravi for rare and serious disease and cancer olaparib / Lynparza,
See also: Tunisia: Doctors Are Worried About "Drug Shortage"
An independent review recalls that cold medicines, such as nasal or nasal edematous vasoconstrictors (ephedrine, naphazoline, oxymetazoline, phenylephrine, pseudoephedrine, are contained in about ten drugs and tuaminoheptan) the risk of serious or even fatal cardiovascular disorders , stroke, heart rhythm disturbances).
At the end of 2017, health authorities banned public advertising of these vasoconstrictors, reports AFP Bruno Toussaint, editor of the editorial board prescribe, “This is a small step, which shows that the authorities admit that these products are problematic, but do not remove them from the market”he adds.
Among the new contacts there are alsoOcaliva appointed with a rare disease, he notes.
The list, published in the February issue of the journal, is freely available on its website (www.prescrire.org).